Access the full text.
Sign up today, get DeepDyve free for 14 days.
S. Lim, M. Jeong, S. Hong, D. Lim, J. Moon, Y. Hong, Ju Kim, Y. Ahn, J. Kang (2008)
Inflammation and delayed endothelization with overlapping drug-eluting stents in a porcine model of in-stent restenosis.Circulation journal : official journal of the Japanese Circulation Society, 72 3
G. Nakazawa, K. Tanabe, J. Aoki, Y. Onuma, Y. Higashikuni, Hirosada Yamamoto, Shuji Ohtsuki, S. Yachi, A. Yagishita, Hiroyoshi Nakajima, K. Hara (2008)
Sirolimus-eluting stents suppress neointimal formation irrespective of metallic allergy.Circulation journal : official journal of the Japanese Circulation Society, 72 6
R. Virmani, G. Guagliumi, A. Farb, G. Musumeci, N. Grieco, T. Motta, Laurian Mihalcsik, M. Tespili, O. Valsecchi, F. Kolodgie (2004)
Localized Hypersensitivity and Late Coronary Thrombosis Secondary to a Sirolimus-Eluting Stent: Should We Be Cautious?Circulation: Journal of the American Heart Association, 109
M. Miglionico, G. Patti, A. D’Ambrosio, G. Sciascio (2008)
Percutaneous coronary intervention utilizing a new endothelial progenitor cells antibody‐coated stent: A prospective single‐center registry in high‐risk patientsCatheterization and Cardiovascular Interventions, 71
Feng Yang, Shichao Feng, Xiang-Jun Pang, Weixiao Li, Y. Bi, Qian Zhao, Shixuan Zhang, Yang Wang, B. Feng (2012)
Combination coating of chitosan and anti-CD34 antibody applied on sirolimus-eluting stents can promote endothelialization while reducing neointimal formationBMC Cardiovascular Disorders, 12
A. Finn, F. Kolodgie, J. Harnek, L. Guerrero, Eduardo Acampado, Kirubel Tefera, K. Skorija, D. Weber, H. Gold, R. Virmani (2005)
Differential Response of Delayed Healing and Persistent Inflammation at Sites of Overlapping Sirolimus- or Paclitaxel-Eluting StentsCirculation, 112
M. Rossi, D. Zavalloni, G. Gasparini, R. Mango, G. Belli, P. Presbitero (2010)
The first report of late stent thrombosis leading to acute myocardial infarction in patient receiving the new endothelial progenitor cell capture stent.International journal of cardiology, 141 1
Sheng Meng, Zongjun Liu, Li Shen, Z. Guo, L. Chou, W. Zhong, Q. Du, J. Ge (2009)
The effect of a layer-by-layer chitosan-heparin coating on the endothelialization and coagulation properties of a coronary stent system.Biomaterials, 30 12
M. Joner, A. Finn, A. Farb, E. Mont, F. Kolodgie, E. Ladich, R. Kutys, K. Skorija, H. Gold, R. Virmani (2006)
Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk.Journal of the American College of Cardiology, 48 1
M. Butzal, S. Loges, M. Schweizer, U. Fischer, U. Gehling, D. Hossfeld, W. Fiedler (2004)
Rapamycin inhibits proliferation and differentiation of human endothelial progenitor cells in vitro.Experimental cell research, 300 1
B. Lagerqvist, S. James, U. Stenestrand, J. Lindbäck, T. Nilsson, L. Wallentin (2007)
Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden.The New England journal of medicine, 356 10
J. Aoki, P. Serruys, H. Beusekom, A. Ong, E. Mcfadden, G. Sianos, W. Giessen, E. Regar, P. Feyter, H. Davis, S. Rowland, M. Kutryk (2005)
Endothelial progenitor cell capture by stents coated with antibody against CD34: the HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) Registry.Journal of the American College of Cardiology, 45 10
G. Nakazawa, M. Vorpahl, A. Finn, J. Narula, R. Virmani (2009)
One step forward and two steps back with drug-eluting-stents: from preventing restenosis to causing late thrombosis and nouveau atherosclerosis.JACC. Cardiovascular imaging, 2 5
Teruo Inoue, M. Sata, Y. Hikichi, Ryoichi Sohma, D. Fukuda, T. Uchida, M. Shimizu, H. Komoda, K. Node (2007)
Mobilization of CD34-Positive Bone Marrow–Derived Cells After Coronary Stent Implantation: Impact on RestenosisCirculation, 115
M. Co., E. Tay, Chi‐Hang Lee, K. Poh, A. Low, Jimmy Lim, Ing-Haan Lim, Y. Lim, H. Tan (2008)
Use of endothelial progenitor cell capture stent (Genous Bio-Engineered R Stent) during primary percutaneous coronary intervention in acute myocardial infarction: intermediate- to long-term clinical follow-up.American heart journal, 155 1
G. Nakazawa, J. Granada, C. Alviar, A. Tellez, G. Kaluza, Margaret Guilhermier, Sherry Parker, S. Rowland, F. Kolodgie, M. Leon, R. Virmani (2010)
Anti-CD34 antibodies immobilized on the surface of sirolimus-eluting stents enhance stent endothelialization.JACC. Cardiovascular interventions, 3 1
Nakazawa (2008)
Sirolimus-eluting stents suppress neointimal formation irrespective of metallic allergyCirc J, 72
J. Daemen, P. Wenaweser, K. Tsuchida, Linda Abrecht, S. Vaina, Cyrill Morger, N. Kukreja, P. Jüni, G. Sianos, G. Hellige, R. Domburg, O. Hess, E. Boersma, B. Meier, S. Windecker, P. Serruys (2007)
Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort studyThe Lancet, 369
Objectives We investigated whether the combination coating of a novel “prohealing coating” hyaluronan‐chitosan (HC) and anti‐CD34 antibody applied on an SES (HCASES) can reduce neointimal formation while promoting endothelialization compared to either agent alone. Background Drug‐eluting stents have considerably reduced the incidence of in‐stent restenosis compared with bare metal stents. However, the beneficial effect of drug elution is overshadowed by delayed re‐endothelialization as well as later “catch‐up” proliferation related to the drug. Methods Three different stents: Sirolimus‐eluting stents (SES), Genous anti‐CD34 antibody stents (GS), and the combination of HC‐anti‐CD34 antibody with sirolimus‐eluting stents (HCASES) were deployed in 54 normal porcine coronary arteries and harvested for scanning electron microscopy (SEM) and histological analysis at 60, 90, and 120 days. Results At 60 and 90 days, SEM analysis showed stent surface endothelial coverage was nearly completed in the HCASES (87 ± 3%, 95 ± 3%) compared with that in the SES (68 ± 6%, 77 ± 8%, P = 0.03). Histological examination at 90 days showed that the HCASES group had less percentage of stenosis than the GS group (P < 0.05). At 120 days, SEM showed a significantly higher extent of endothelial coverage above struts in the HCASES (96 ± 2%) and the GS (95 ± 3%) as compared with the SES group (66 ± 3%; P = 0.02). The HCASES group showed less stenosis than that in the GS group (P < 0.05), but it was not significantly different from the SES group (P = 0.063). Conclusions Histological and SEM analyses demonstrate that the HCASES can reduce neointimal formation and inflammation while promoting endothelialization in the long term. (J Interven Cardiol 2015;28:257–263)
Journal of Interventional Cardiology – Wiley
Published: Jun 1, 2015
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.